RLAY
Relay Therapeutics, Inc.
Price Chart
Latest Quote
$15.88
+0.32 (+2.06%)
Current Price
| Previous Close | $15.56 |
| Open | $15.99 |
| Day High | $16.40 |
| Day Low | $15.82 |
| Volume | 7,468,919 |
Stock Information
| Shares Outstanding | 217.94M |
| Total Debt | $31.57M |
| Cash Equivalents | $642.07M |
| Revenue | $10.68M |
| Net Income | $-272.70M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.46B |
| EPS (TTM) | $-1.56 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.43B |
| Sales | $10.68M |
| Income | $-272.70M |
| Book/sh | $3.39 |
| Cash/sh | $2.95 |
| Employees | 193 |
Financial Ratios
| Quick Ratio | 21.58 |
| Current Ratio | 22.13 |
| Debt/Eq | 4.92 |
Returns & Margins
| ROA | -24.72% |
| ROE | -40.01% |
| Operating Margin | -2619.67% |
Ownership
| Insider Ownership | 1.39% |
| Institutional Ownership | 86.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.62 |
| P/S | 324.18 |
| P/B | 4.68 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $24.82 |
Technical Indicators
| SMA20 | $14.44 |
| SMA50 | $14.17 |
| SMA200 | $9.31 |
| RSI | 62.38 |
| ATR | 1.0996 |
| Shares Float | 136.02M |
| Short Float | 18.39% |
| Short Ratio | 8.17 |
| Volatility | 1.75 |
| Rel Volume | 2.44 |
Performance History
| Week | +11.52% |
| Month | +31.57% |
| Quarter | +58.80% |
| 6 Months | +87.26% |
| YTD | +94.13% |
| Year | +418.95% |
| 3 Years | +34.80% |
| 5 Years | -53.59% |
| 10 Years | -54.69% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $15.88 | 10,739,000 |
| 2026-06-17 | $15.56 | 2,863,500 |
| 2026-06-16 | $15.05 | 2,338,400 |
| 2026-06-15 | $14.96 | 1,879,800 |
| 2026-06-12 | $14.81 | 1,770,100 |
| 2026-06-11 | $14.24 | 2,092,700 |
| 2026-06-10 | $13.49 | 2,520,700 |
| 2026-06-09 | $14.09 | 2,963,900 |
| 2026-06-08 | $13.66 | 2,917,400 |
| 2026-06-05 | $13.52 | 6,071,400 |
| 2026-06-04 | $14.54 | 5,790,400 |
| 2026-06-03 | $15.30 | 3,726,900 |
| 2026-06-02 | $15.70 | 11,483,200 |
| 2026-06-01 | $14.26 | 2,260,600 |
| 2026-05-29 | $14.05 | 3,464,200 |
| 2026-05-28 | $13.90 | 3,951,500 |
| 2026-05-27 | $14.43 | 3,050,300 |
| 2026-05-26 | $14.17 | 2,373,500 |
| 2026-05-22 | $13.53 | 5,355,200 |
| 2026-05-21 | $13.66 | 10,420,400 |
| 2026-05-20 | $13.02 | 6,519,400 |
| 2026-05-19 | $12.07 | 17,856,600 |
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why
Insider Monkey âĸ 2026-06-11T10:20:38Z
Is Relay Therapeutics a Buy After Promising Trial Results?
Motley Fool âĸ 2026-05-22T21:50:00Z
Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release
Simply Wall St. âĸ 2026-05-22T02:16:06Z
Why Relay Therapeutics Stock Popped on Wednesday
Motley Fool âĸ 2026-05-20T23:21:49Z
This Biotech's Drug Just Wiped The Floor With Forecasts
Investor's Business Daily âĸ 2026-05-19T20:06:39Z
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
MT Newswires âĸ 2026-05-19T18:02:34ZRising Bond Yields Weigh on Stocks
Barchart âĸ 2026-05-19T15:21:52Z
Stocks Pressured by Tech Weakness and Rising Bond Yields
Barchart âĸ 2026-05-19T14:13:02Z
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)
InvestorsHub âĸ 2026-05-19T13:31:18Z
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Tuesday Amid Uncertainty Surrounding US-Iran Talks
MT Newswires âĸ 2026-05-19T13:14:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $15,355,000 | $10,007,000 | $25,546,000 | $1,381,000 |
| Operating Revenue | $15,355,000 | $10,007,000 | $25,546,000 | $1,381,000 |
| Expenses | ||||
| Total Expenses | $318,093,000 | $395,681,000 | $404,968,000 | $312,333,000 |
| Other Income Expense | $-776,000 | $13,220,000 | $6,404,000 | $11,657,000 |
| Other Non Operating Income Expenses | $-776,000 | $14,000 | $-18,000 | $-20,000 |
| Net Non Operating Interest Income Expense | $27,035,000 | $34,746,000 | $31,045,000 | $8,786,000 |
| Operating Expense | $318,093,000 | $395,681,000 | $404,968,000 | $312,333,000 |
| General And Administrative Expense | $56,710,000 | $76,592,000 | $74,950,000 | $65,978,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Net Interest Income | $27,035,000 | $34,746,000 | $31,045,000 | $8,786,000 |
| Interest Income | $27,035,000 | $34,746,000 | $31,045,000 | $8,786,000 |
| Normalized Income | $-276,479,000 | $-350,914,000 | $-348,395,000 | $-302,186,000 |
| Net Income From Continuing And Discontinued Operation | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Total Operating Income As Reported | $-302,738,000 | $-372,468,000 | $-373,000,000 | $-299,275,000 |
| Net Income Common Stockholders | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Net Income | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Net Income Including Noncontrolling Interests | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Net Income Continuous Operations | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Pretax Income | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Special Income Charges | $0 | $13,206,000 | $6,422,000 | $11,677,000 |
| Interest Income Non Operating | $27,035,000 | $34,746,000 | $31,045,000 | $8,786,000 |
| Operating Income | $-302,738,000 | $-385,674,000 | $-379,422,000 | $-310,952,000 |
| Per Share | ||||
| Diluted EPS | $-1.61 | $-2.36 | $-2.79 | $-2.59 |
| Basic EPS | $-1.61 | $-2.36 | $-2.79 | $-2.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-299,181,000 | $-393,416,000 | $-380,575,000 | $-318,499,000 |
| Total Unusual Items | $0 | $13,206,000 | $6,422,000 | $11,677,000 |
| Total Unusual Items Excluding Goodwill | $0 | $13,206,000 | $6,422,000 | $11,677,000 |
| Reconciled Depreciation | $3,557,000 | $5,464,000 | $5,269,000 | $4,130,000 |
| EBITDA (Bullshit earnings) | $-299,181,000 | $-380,210,000 | $-374,153,000 | $-306,822,000 |
| EBIT | $-302,738,000 | $-385,674,000 | $-379,422,000 | $-310,952,000 |
| Diluted Average Shares | $171,586,558 | $142,867,844 | $122,576,527 | $112,233,649 |
| Basic Average Shares | $171,586,558 | $142,867,844 | $122,576,527 | $112,233,649 |
| Diluted NI Availto Com Stockholders | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Restructuring And Mergern Acquisition | $0 | $-13,206,000 | $-6,422,000 | $-11,677,000 |
| Research And Development | $261,383,000 | $319,089,000 | $330,018,000 | $246,355,000 |
| Selling General And Administration | $56,710,000 | $76,592,000 | $74,950,000 | $65,978,000 |
| Other Gand A | $56,710,000 | $76,592,000 | $74,950,000 | $65,978,000 |
| Other Special Charges | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $567,060,000 | $775,492,000 | $749,703,000 | $947,918,000 |
| Total Assets | $621,331,000 | $871,296,000 | $843,980,000 | $1,099,771,000 |
| Total Non Current Assets | $43,052,000 | $62,092,000 | $73,877,000 | $80,266,000 |
| Other Non Current Assets | $1,336,000 | $2,119,000 | $2,707,000 | $2,578,000 |
| Goodwill And Other Intangible Assets | $0 | $2,300,000 | $2,300,000 | $2,300,000 |
| Current Assets | $578,279,000 | $809,204,000 | $770,103,000 | $1,019,505,000 |
| Other Current Assets | $5,974,000 | $10,533,000 | $3,315,000 | $3,259,000 |
| Prepaid Assets | $17,787,000 | $17,348,000 | $16,702,000 | $12,110,000 |
| Cash Cash Equivalents And Short Term Investments | $554,518,000 | $781,323,000 | $750,086,000 | $998,917,000 |
| Cash And Cash Equivalents | $84,018,000 | $124,287,000 | $143,736,000 | $151,794,000 |
| Receivables | - | - | $0 | $5,219,000 |
| Accounts Receivable | - | - | $0 | $306,000 |
| Other Receivables | - | - | - | $4,913,000 |
| Debt | ||||
| Total Debt | $32,458,000 | $48,502,000 | $53,466,000 | $57,742,000 |
| Long Term Debt And Capital Lease Obligation | $28,693,000 | $42,775,000 | $48,502,000 | $53,466,000 |
| Current Debt And Capital Lease Obligation | $3,765,000 | $5,727,000 | $4,964,000 | $4,276,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $54,271,000 | $93,504,000 | $91,977,000 | $149,553,000 |
| Total Non Current Liabilities Net Minority Interest | $28,693,000 | $42,775,000 | $61,708,000 | $85,844,000 |
| Current Liabilities | $25,578,000 | $50,729,000 | $30,269,000 | $63,709,000 |
| Other Current Liabilities | $463,000 | $1,990,000 | $1,204,000 | $26,152,000 |
| Current Deferred Liabilities | $0 | $7,679,000 | $0 | $0 |
| Payables And Accrued Expenses | $21,350,000 | $35,227,000 | $23,399,000 | $32,238,000 |
| Payables | $7,705,000 | $14,097,000 | $9,211,000 | $10,578,000 |
| Accounts Payable | $7,705,000 | $14,097,000 | $9,211,000 | $10,578,000 |
| Other Non Current Liabilities | - | - | $13,206,000 | $32,378,000 |
| Equity | ||||
| Common Stock Equity | $567,060,000 | $777,792,000 | $752,003,000 | $950,218,000 |
| Total Equity Gross Minority Interest | $567,060,000 | $777,792,000 | $752,003,000 | $950,218,000 |
| Stockholders Equity | $567,060,000 | $777,792,000 | $752,003,000 | $950,218,000 |
| Gains Losses Not Affecting Retained Earnings | $733,000 | $-991,000 | $-196,000 | $-10,420,000 |
| Other Equity Adjustments | $733,000 | $-991,000 | $-196,000 | $-10,420,000 |
| Retained Earnings | $-2,014,769,000 | $-1,738,290,000 | $-1,400,582,000 | $-1,058,609,000 |
| Other | ||||
| Ordinary Shares Number | $173,868,949 | $167,755,715 | $127,462,409 | $121,112,234 |
| Share Issued | $173,868,949 | $167,755,715 | $127,462,409 | $121,112,234 |
| Tangible Book Value | $567,060,000 | $775,492,000 | $749,703,000 | $947,918,000 |
| Invested Capital | $567,060,000 | $777,792,000 | $752,003,000 | $950,218,000 |
| Working Capital | $552,701,000 | $758,475,000 | $739,834,000 | $955,796,000 |
| Capital Lease Obligations | $32,458,000 | $48,502,000 | $53,466,000 | $57,742,000 |
| Total Capitalization | $567,060,000 | $777,792,000 | $752,003,000 | $950,218,000 |
| Additional Paid In Capital | $2,580,928,000 | $2,516,905,000 | $2,152,654,000 | $2,019,126,000 |
| Capital Stock | $168,000 | $168,000 | $127,000 | $121,000 |
| Common Stock | $168,000 | $168,000 | $127,000 | $121,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $28,693,000 | $42,775,000 | $48,502,000 | $53,466,000 |
| Current Deferred Revenue | $0 | $7,679,000 | $0 | $0 |
| Current Capital Lease Obligation | $3,765,000 | $5,727,000 | $4,964,000 | $4,276,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $0 | $106,000 | $702,000 | $1,043,000 |
| Current Accrued Expenses | $13,645,000 | $21,130,000 | $14,188,000 | $21,660,000 |
| Net PPE | $41,716,000 | $57,673,000 | $68,870,000 | $75,388,000 |
| Accumulated Depreciation | $-21,547,000 | $-28,912,000 | $-23,582,000 | $-18,389,000 |
| Gross PPE | $63,263,000 | $86,585,000 | $92,452,000 | $93,777,000 |
| Leases | $908,000 | $3,825,000 | $3,826,000 | $3,826,000 |
| Construction In Progress | $0 | $69,000 | $1,577,000 | $1,220,000 |
| Other Properties | $60,576,000 | $79,169,000 | $83,527,000 | $85,226,000 |
| Machinery Furniture Equipment | $1,779,000 | $3,522,000 | $3,522,000 | $3,505,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $470,500,000 | $657,036,000 | $606,350,000 | $847,123,000 |
| Treasury Shares Number | - | - | $0 | - |
| Restricted Common Stock | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-235,865,000 | $-251,125,000 | $-304,442,000 | $-238,552,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-235,455,000 | $-249,107,000 | $-300,316,000 | $-229,490,000 |
| Cash Flow From Continuing Operating Activities | $-235,455,000 | $-249,107,000 | $-300,316,000 | $-229,490,000 |
| Operating Gains Losses | $1,003,000 | $-101,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-410,000 | $-2,018,000 | $-4,126,000 | $-9,062,000 |
| Investing Cash Flow | $192,799,000 | $-41,083,000 | $257,634,000 | $-188,745,000 |
| Cash Flow From Continuing Investing Activities | $192,799,000 | $-41,083,000 | $257,634,000 | $-188,745,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $265,892,000 | $30,281,000 | $284,744,000 |
| Financing Cash Flow | $1,604,000 | $270,153,000 | $34,753,000 | $289,910,000 |
| Cash Flow From Continuing Financing Activities | $1,604,000 | $270,153,000 | $34,753,000 | $289,910,000 |
| Net Common Stock Issuance | $0 | $265,892,000 | $30,281,000 | $284,744,000 |
| Common Stock Issuance | $0 | $265,892,000 | $30,281,000 | $284,744,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $85,354,000 | $126,406,000 | $146,443,000 | $154,372,000 |
| Beginning Cash Position | $126,406,000 | $146,443,000 | $154,372,000 | $282,697,000 |
| Changes In Cash | $-41,052,000 | $-20,037,000 | $-7,929,000 | $-128,325,000 |
| Proceeds From Stock Option Exercised | $1,604,000 | $4,261,000 | $4,472,000 | $5,166,000 |
| Net Investment Purchase And Sale | $193,209,000 | $-39,065,000 | $261,760,000 | $-179,683,000 |
| Sale Of Investment | $316,180,000 | $611,564,000 | $647,302,000 | $355,736,000 |
| Purchase Of Investment | $-122,971,000 | $-650,629,000 | $-385,542,000 | $-535,419,000 |
| Net PPE Purchase And Sale | $-410,000 | $-2,018,000 | $-4,126,000 | $-9,062,000 |
| Purchase Of PPE | $-410,000 | $-2,018,000 | $-4,126,000 | $-9,062,000 |
| Change In Working Capital | $-23,306,000 | $14,620,000 | $-32,458,000 | $11,246,000 |
| Change In Other Working Capital | $-11,951,000 | $8,922,000 | $1,509,000 | $-8,380,000 |
| Change In Other Current Liabilities | $-1,527,000 | $786,000 | $-24,948,000 | $10,756,000 |
| Change In Payables And Accrued Expense | $-11,440,000 | $10,268,000 | $-9,590,000 | $11,289,000 |
| Change In Prepaid Assets | $1,612,000 | $-5,356,000 | $-4,648,000 | $-2,140,000 |
| Change In Receivables | $0 | $0 | $5,219,000 | $-279,000 |
| Changes In Account Receivables | $0 | $0 | $306,000 | $97,000 |
| Stock Based Compensation | $62,419,000 | $94,139,000 | $86,031,000 | $56,138,000 |
| Asset Impairment Charge | $2,300,000 | $0 | $0 | - |
| Amortization Of Securities | $-4,949,000 | $-12,315,000 | $-10,763,000 | $1,182,000 |
| Depreciation Amortization Depletion | $3,557,000 | $5,464,000 | $5,269,000 | $4,130,000 |
| Depreciation And Amortization | $3,557,000 | $5,464,000 | $5,269,000 | $4,130,000 |
| Depreciation | $3,557,000 | $5,464,000 | $5,269,000 | $4,130,000 |
| Gain Loss On Sale Of PPE | $1,003,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-276,479,000 | $-337,708,000 | $-341,973,000 | $-290,509,000 |
| Other Non Cash Items | - | $-13,206,000 | $-6,422,000 | $-11,677,000 |
| Gain Loss On Investment Securities | - | $-101,000 | - | - |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | $0 | $0 |
| Change In Accrued Expense | - | - | $-32,144,000 | $20,056,000 |
| Change In Payable | - | - | $-2,394,000 | $1,989,000 |
| Change In Account Payable | - | - | $-2,394,000 | $1,989,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-19